- Home
- RDCM vs TVRD Comparison
RDCM vs TVRD Comparison
Compare RDCM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- TVRD
- Stock Information
- Founded
- RDCM 1985
- TVRD 2017
- Country
- RDCM Israel
- TVRD United States
- Employees
- RDCM N/A
- TVRD N/A
- Industry
- RDCM Computer peripheral equipment
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- RDCM Technology
- TVRD Health Care
- Exchange
- RDCM Nasdaq
- TVRD Nasdaq
- Market Cap
- RDCM 210.3M
- TVRD 246.5M
- IPO Year
- RDCM 1997
- TVRD N/A
- Fundamental
- Price
- RDCM $13.41
- TVRD $28.34
- Analyst Decision
- RDCM Strong Buy
- TVRD Strong Buy
- Analyst Count
- RDCM 2
- TVRD 2
- Target Price
- RDCM $16.00
- TVRD $52.00
- AVG Volume (30 Days)
- RDCM 62.5K
- TVRD 48.4K
- Earning Date
- RDCM 05-14-2025
- TVRD 05-13-2025
- Dividend Yield
- RDCM N/A
- TVRD N/A
- EPS Growth
- RDCM 111.69
- TVRD N/A
- EPS
- RDCM 0.53
- TVRD N/A
- Revenue
- RDCM $63,477,000.00
- TVRD N/A
- Revenue This Year
- RDCM $16.58
- TVRD N/A
- Revenue Next Year
- RDCM $11.48
- TVRD N/A
- P/E Ratio
- RDCM $25.35
- TVRD N/A
- Revenue Growth
- RDCM 18.21
- TVRD N/A
- 52 Week Low
- RDCM $9.05
- TVRD $8.13
- 52 Week High
- RDCM $15.98
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- RDCM 61.29
- TVRD N/A
- Support Level
- RDCM $12.65
- TVRD N/A
- Resistance Level
- RDCM $13.55
- TVRD N/A
- Average True Range (ATR)
- RDCM 0.67
- TVRD 0.00
- MACD
- RDCM 0.01
- TVRD 0.00
- Stochastic Oscillator
- RDCM 51.15
- TVRD 0.00
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.